LGD-2226
LGD-2226 is an experimental non-steroidal SARM from Ligand Pharmaceuticals studied in rodents for anabolic effects on muscle and bone with reduced prostate stimulation. It predates the better-known LGD-4033 and has no human clinical data.
01 Overview
LGD-2226 was among the early SARMs characterised by Ligand Pharmaceuticals in the mid-2000s. In male rat models it increased muscle mass, bone strength, and sexual behaviour while producing less prostate enlargement than testosterone, supporting a selective anabolic profile.
LGD-2226 was not developed into a marketed product and has no published human trials. It is uncommon even in the grey market. All information reflects animal studies, and human dosing or safety cannot be inferred with confidence.
02 Mechanism
Non-steroidal androgen receptor agonist producing anabolic effects in muscle and bone with attenuated androgenic activity in the prostate in preclinical models.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Anecdotal | 10–20 mg/day | Oral | No human data; speculative range. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Increased muscle massAnabolic effect on skeletal muscle in male rat models. | Preclinical | ||
| Increased bone strengthImproved bone mineral density and mechanical strength in rodents. | Preclinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| HPTA suppressionAR agonism suppresses endogenous testosterone; unmeasured in humans. | Moderate | Expected | Preclinical | |
| Uncharacterised toxicityNo human safety data. | Moderate | Uncharacterised | Unconfirmed |